Accordingly, it also increases the importance of existence and establishing a therapeutic window, describing the dose and period of time of treatment, which may be based on tumor PDE10A expression and PI3K/PTEN status, to maximize efficacy while minimizing the risks of compensatory signaling. This evidence concerns the gene PDE10A and neoplasm.